Biblio

Szerző Cím [ Típus(Desc)] Év
Szűrők: Szerző is Ylä-Herttuala, Seppo  [Minden szűrő visszaállítása]
Journal Article
Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, et al.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835PDF ikon Andrey Anisimov et al., Circulation Research 2009 (8.03 MB)PDF ikon Andrey Anisimov et al., Circulation Research 2009, supplement (5.9 MB)
Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, et al.. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J [Internet]. 2002;16(9):1041 - 9. http://view.ncbi.nlm.nih.gov/pubmed/12087065PDF ikon Anne Saaristo et al., FASEB Journal 2002 (966.08 KB)
Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am J Pathol. 2012;181(5):1607-20.
Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, et al.. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733PDF ikon Tuomas Tammela et al., Circulation Research 2007 (1.1 MB)
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, et al.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF ikon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF ikon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF ikon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, et al.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085PDF ikon Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB)PDF ikon Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF ikon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF ikon Maija Bry et al., Circulation 2010 (2.23 MB)PDF ikon Maija Bry et al., Circulation 2010, supplement (17.77 MB)